Sirona Biochem Announces Development of Anti-Wrinkle Treatment and Update from J.P. Morgan Healthcare Conference
Momentum Public Relations
Press Release: January 31, 2018
Sirona Biochem Corp. (TSX VENTURE: SBM)(FRANKFURT: ZSB)(XETRA: ZSB) (the “Company”) announced today that the Company is developing an anti-wrinkle therapy.
The compound, LIP-01, was discovered to have a novel mechanism of action and will enter pre-clinical studies as a plumping/smoothing ingredient for aging skin. LIP-01 was tested on human skin cells called “normal human dermal fibroblasts” (NHDF). The treatment of the cells with the compound LIP-01 resulted in an up-regulation of gene expression leading to an activation of the signaling pathway of lipids. The presence of lipid vesicles in fibroblasts treated by compound LIP-01 showed cell differentiation of fibroblasts into lipo-fibroblasts. The increased synthesis of lipids in these cells leads to a plumping effect which is anticipated to fill wrinkles. Sirona’s scientists have also observed proliferation and preservation of fibroblasts when LIP-01 was added, important in countering the declining number of cells observed in aged skin. The Company and its consultants are building a development plan for this compound which includes a proof-of-concept clinical trial.
Loss of elasticity and degradation of fat tissue are two markers seen in aging skin, leading to the appearance of lines and wrinkles. Compounds that increase the number and volume of adipocytes (fat cells) can act as plumping, volumizing, and densifying skin agents, thereby reducing the visibility of wrinkle and potentially providing a more youthful look. The global anti-aging market is expected to grow to over $330 Billion USD by 2021 (Reuters, June 2017). Novel solutions are actively being sought out by the dermatology industry to address this.
“There was tremendous interest in these initial results when presented to companies on our recent trip to San Francisco during the J.P. Morgan Healthcare Conference,” said Dr. Howard Verrico, CEO. “The effects of compound LIP-01 on the skin cells suggest that this compound can contribute to improving the quality of dry skin and reduce the signs of aging. Our goal is to develop LIP-01 as a non-invasive treatment for wrinkles by a mechanism very different from dermal fillers and Botox®1.”
According to the American Society of Plastic Surgeons, using Botox® treatment for wrinkles is the most common cosmetic operation performed, generating 3 billion USD in revenue annually. However, Botox® is generally limited to use on the upper third of the face, specifically the frown lines between the eyebrows. Botox® also requires administration by a properly trained professional.
“Our scientists believe these two obstacles could be overcome with a topical therapy which could either replace or augment Botox® treatments. If clinically successful, LIP-01 could exceed Botox in market potential,” Verrico said.
In San Francisco, the Sirona team met with existing potential partners and established new ones in the cosmetic and dermatology industry to discuss both the skin-lightening portfolio and introduce LIP-01. The Company is pleased with the positive outcome of each meeting and is looking forward to continuing discussions during the American Academy of Dermatology Summit next month in San Diego. Several leading dermatologists who were excited by the data will be meeting with the Company to discuss next steps. Sirona Biochem is now in discussions with over a dozen companies regarding various aspects of the Company’s pipeline.
Sirona’s management also met with Obagi’s medical strategic development team to explore opportunities to commercialize its next-generation skin lighteners under a new agreement. The new skin lighteners are superior to its first-generation ones, having a simple synthetic pathway which results in a lower cost of goods. The first-generation compound, TFC-849, has proven difficult to manufacture in a commercially viable process. Obagi Medical under its new ownership will not be proceeding with the development of TFC-849. As a result, Sirona’s skin lightener library is no longer encumbered by restrictive clauses under the former licensing agreement and is now available for licensing world-wide.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is located in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
(1) BOTOX COSMETIC® is a registered trademark of Allergan Inc.
For more information regarding this press release, please contact:
Christopher Hopton
CFO
Sirona Biochem Corp.
Phone: 1.604.282.6064
Email: chopton@sironabiochem.com
- Published in Sirona Biochem
AREV Nutrition Sciences Inc. Announces a Reverse Takeover Transaction with we Grow BC Ltd.
Momentum Public Relations
Press Release: 2018-01-17
AREV Nutrition Sciences Inc. (” AREV ” or the “Company”) ( CSE – AREV ), is pleased to announce a binding agreement (the “Acquisition Agreement”) to acquire 100% of the issued and outstanding shares of We Grow BC Ltd. (“WGBC”).
WGBC is a private company strategically located in Creston British Columbia in the heart of the Kootenay’s, where BC grown marijuana originated, and holds a Cultivation License pursuant to the Access to Cannabis for Medical Purposes Regulations under Health Canada. The Company has scalable production facilities currently consisting of 100 acres of land with 100,000 square feet of indoor space of which 24,000 has been retrofitted for Phase 1 Cultivation.
The Acquisition Agreement provides for each shareholder of WGBC to receive 90,909 shares of AREV in exchange for each share of WGBC based on a $50,000,000 valuation of WGBC. It is anticipated a total of 100,000,000 AREV shares will be issued at a deemed price of $0.50 per AREV Share pursuant to the agreement.
AREV’s intention is to enter into an amalgamation by plan of arrangement where the amalgamation shall take place between a wholly owned subsidiary of AREV and WGBC.
AREV intends to call a Special Annual General meeting in order to approve the transaction and to affix its board of directors to 7 members of which 4 will be designated by WGBC.
The deemed aggregate value of $50,000,000 ($50 million) attributable to such 100,000,000 AREV shares shall be supported by a valuation of WGBC. Also, it is understood that the AREV shares to be issued by AREV to the WGBC Shareholders may be subject to certain resale restrictions including escrow requirements under applicable securities law and policies of the Canadian Securities Exchange (the “CSE”). ;
Both companies will have 5 business days from the date of execution of the Acquisition Agreement to provide the other party complete and commercially reasonable requests for due diligence.
The proposed acquisition of WGBC constitutes a fundamental change under the policies of the “CSE”. and shall be subject to shareholder and CSE approval. Accordingly, trading of AREV shares has been halted pending acceptance of the Acquisition Agreement by the CSE and the acceptance and posting of regulatory filings in connection with the Acquisition Agreement under the Company’s CSE profile.
“We believe this to be the perfect synergy between both companies, with AREV having the extraction technology and finished products and We Grow’s current 24,000 square feet grow facility and up to 100 acre cultivation abilities in the Kootenays,” stated Mike Withrow, AREV Chairman.
Further to the Company’s news release of October 31, 2017, the Company announces that it will not be proceeding with the letter of intent to acquire Verified Plant Genetics and a certain property in Parksville, British Columbia. The Company will revisit this transaction in the future.
For further information, contact Stephane Maher, CEO at stephane@arevnutrition.com.
On behalf of the Board,
Mike Withrow, Chairman.
About AREV Nutrition Sciences Inc.
AREV Nutrition Sciences Inc. (“AREV”) produces and delivers functional ingredients from its world-class extraction systems. AREV is revolutionizing the current delivery method of coconut oil, whey protein and nutrients through emulsification. These premium ingredients and products are targeted for the natural health, medical, functional food, nutraceutical, sport nutrition and bioceutical markets. AREV is also working with Pharmacy and Dispensary operators with an innovative emulsified base formula to disperse Cannabis oil extracts from specific selected genetic Cannabis strains that address 5 areas of health including Anxiety, Pain Management, Insomnia, Central Nervous System Disorders & Libido.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
FORWARD LOOKING INFORMATION
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws. This press release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company’s Management’s Discussion and Analysis under the Company’s profile on www.sedar.com.
- Published in AREV Nutrition Sciences
AREV Nutrition Sciences Inc. Announces Attendance At Capital Events Bahamas, Conversion Of The Convertible Debenture And Issuance Of Stock Options
Momentum Public Relations
Press Release: January 9, 2018
AREV Nutrition Sciences Inc. (” AREV ” or the “Company”) ( CNSX – ARV ), is pleased to announce that that they will be attending the AlphaNorth Capital Conference at the Atlantis Paradise Island Resort in the Bahamas from January 12 – 14, 2018, hosted by Capital Event Conferences. The conference introduces growth-stage companies (Resource, Technology, Biotech, Special Situations) to active top-level capital finance individuals through a day of scheduled one-on-one meetings.
The Company is also pleased to announce that Chiron Capital Inc., a company directly controlled by Mike Withrow, has converted the second of two convertible debentures into units of the Company, each unit consisting of a common share of the Company and a common share warrant of the Company. The total principal amount of the convertible debentures exercised is $300,000. The convertible debentures has been converted into units of the Company at a conversion price of $0.05 per unit with a term ending September 16, 2018.
The conversion of this Convertible Debenture retires long term debt of the C ompany.
After converting the debenture, Chiron Capital Inc., has exercised 2,000,000 warrants at a price of $0.05 per common share for a total cost of $100,000.
If all of Mike Withrow’s convertible securities were converted into common shares of the Company Mike Withrow would control 18,112,000 (42%) of a total of 43,342,800 fully diluted common shares of the Company.
For further information, contact Stephane Maher, CEO at stephane@arevnutrition.com.
On behalf of the Board,
Stephane Maher
Chief Executive Officer & Director
About AREV Nutrition Sciences Inc.
AREV Nutrition Sciences Inc. (“AREV”), produces and delivers functional ingredients from its world-class extraction system. AREV is revolutionizing the current delivery method of coconut oil, whey protein and nutrients through emulsification. These premium ingredients and products are targeted for the natural health, medical, functional food, nutraceutical, sport nutrition and bioceutical markets. AREV is also working with Pharmacy and Dispensary operators with an innovative emulsified base formula to disperse Cannabis oil extracts from specific selected genetic Cannabis strains that address 5 areas of health including Anxiety, Pain management, Insomnia, Central Nervous System Disorders & Sexuality.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
FORWARD LOOKING INFORMATION
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.This press release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company’s Management’s Discussion and Analysis under the Company’s profile on www.sedar.com.
Copyright (c) 2018 TheNewswire – All rights reserved.
- Published in AREV Nutrition Sciences, Marijuana, Uncategorized
- 1
- 2